normal human stomach antrum Search Results


99
ATCC by nc nd license
By Nc Nd License, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/by nc nd license/product/ATCC
Average 99 stars, based on 1 article reviews
by nc nd license - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

96
AMS Biotechnology total rna - human adult normal tissue: stomach
Total Rna Human Adult Normal Tissue: Stomach, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total rna - human adult normal tissue: stomach/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
total rna - human adult normal tissue: stomach - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

92
Novus Biologicals fundus tissue slides
Fundus Tissue Slides, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fundus tissue slides/product/Novus Biologicals
Average 92 stars, based on 1 article reviews
fundus tissue slides - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
Novus Biologicals human stomach tissue
Human Stomach Tissue, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human stomach tissue/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
human stomach tissue - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

92
BioChain Institute cdna
Cdna, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdna/product/BioChain Institute
Average 92 stars, based on 1 article reviews
cdna - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

93
TaKaRa tumor cdna
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Tumor Cdna, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tumor cdna/product/TaKaRa
Average 93 stars, based on 1 article reviews
tumor cdna - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Novus Biologicals novus biologicals nbp2 30203
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Novus Biologicals Nbp2 30203, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/novus biologicals nbp2 30203/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
novus biologicals nbp2 30203 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

97
ATCC human stomach cancer cells
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Human Stomach Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human stomach cancer cells/product/ATCC
Average 97 stars, based on 1 article reviews
human stomach cancer cells - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

90
BioChain Institute cdnas from 14 normal human tissues
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Cdnas From 14 Normal Human Tissues, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdnas from 14 normal human tissues/product/BioChain Institute
Average 90 stars, based on 1 article reviews
cdnas from 14 normal human tissues - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

94
TaKaRa human tissues
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Human Tissues, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human tissues/product/TaKaRa
Average 94 stars, based on 1 article reviews
human tissues - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
TaKaRa stomach rnas
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Stomach Rnas, supplied by TaKaRa, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stomach rnas/product/TaKaRa
Average 94 stars, based on 1 article reviews
stomach rnas - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

90
Broad Institute Inc tcga rna-seq normalized matrix
, Expression of CDO1 in cell lines was examined by RT-PCR <t>or</t> <t>qRT-PCR</t> analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched <t>cDNA</t> prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.
Tcga Rna Seq Normalized Matrix, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tcga rna-seq normalized matrix/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
tcga rna-seq normalized matrix - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


, Expression of CDO1 in cell lines was examined by RT-PCR or qRT-PCR analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched cDNA prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.

Journal: PLoS ONE

Article Title: Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers

doi: 10.1371/journal.pone.0044951

Figure Lengend Snippet: , Expression of CDO1 in cell lines was examined by RT-PCR or qRT-PCR analyses. m, mock treatment. a, 5-Aza-dC treatment (5 µM for three days). β-actin was used as a loading control. Methylation status of CDO1 promoter in each cell line was examined and indicated as M for methylation, U for unmethylation, and M/U for co-existence of methylated and unmethylated alleles. CDO1 was completely methylated in all cancer cell lines since only cytosine peaks were observed in CpGs sequenced (100% methylation) while it was not methylated in HEK293 since only thymidine peaks were observed (0% methylation). CDO1 was partially methylated in MCF-12A since both methylated and unmethylated alleles were observed in 10 CpGs of the CDO1 promoters examined. When a cytosine peak were compared with a thymidine peak in each CpG of the 10 CpGs, cytosine peaks were dominant (methylated), but since these “methylated CpGs” were found in less than 50% of total CpGs (10/34), it was considered as “methylation-negative” according to the criteria described in . B . qRT-PCR was performed in cDNAs derived from patients with colon, breast, esophagus, bladder and stomach cancer (T) and patients without cancer (NN) (upper). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of CDO1 to an internal control gene, β-actin. The CDO1 expression level was determined in 10 lung cancer patients and 10 patients without cancer (lower). 2?-()*100, the expression of CDO1 relative to β-actin calculated based on the threshold cycle (C t ) as 2 −ΔCt (ΔCt = C t, CDO1 - C t,β-actin ). Experiments were done in duplicate, and values indicate means ± SD. *, P<0.05 in T- test. C , The CDO1 expression level was examined in five pairs (A ∼ E) of matched cDNA prepared from patients with colon and lung cancer. PT, primary tumor; PN, matched normal tissues.

Article Snippet: For the qRT-PCR analysis, five matched normal and tumor cDNA (A ∼ E) were purchased from Clontech Laboratories, Inc. (Mountain View, CA). cDNA panels of human normal (NN) and cancer tissue (T) derived from colon, breast, esophagus, bladder and stomach were purchased from BioChain Institute, Inc. (Hayward, CA).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Control, Methylation, Derivative Assay